Neoadjuvant chemoradiotherapy for resectable esophageal cancer：an in-depth study of randomized controlled trials and literature review.pdfVIP

CancerBiolMed2014；11：191-201．doi：10．7497／j．issn．2095-3941．2014．03．005 REVIEW Neoadjuvantchemoradiotherapyforresectableesophageal cancer：anin—-depthstudyofrandomizedcontrolledtrialsand Iiteraturereview Xiao—FengDuan，PengTang，Zhen—TaoYu DepartmentofEsophagealCancer,TianjinMedicalUniversityCancerInstituteandHospital，Tianjin300060，China Surgeryfollowingneoadjuvantchemoradiotherapy(NCRT)isacommonmultjdjscjp1jnaytreatmentforresectable esophagealcancer(EC)．Afteranalyzing12randomizedcontrolledtrials(RCTs)，wediscussthekeyissuesofsurgeryin themanagementofresectableEC．M ongwithchemoradiotherap)~NCRTisrecommendedforpatientswithsquamous cellcarcinoma(SCC)andadenocarcinoma(AC)Jandmostchemotherapyregimensarebasedoncisplatin，fluorouracil (FU)，orboth(CF)．However,taxane—basedschedulesoradditionalstudiesJtogetherwithnewerchemotherapiesJare warranted．Innineclinicaltrials，post-operativecomplicationsweresimilarwithoutsignificantdifferencesbetweentwo treatmentgroups．In—hospitalmortalitywassignificantlydifferentinonly1outof10trials．Halfoftherandomizedtrialsthat compareNCRTwithsurgeryinECdemonstrateanincreaseinoverallsurvivalordisease-freesurviva1．NCRToffersagreat opportunityformarginnegativeresection，decreaseddiseasestage，andimprovedloco—regionalcontro1．However,NCRT doesnotaffectthequalityoflifewhencombinedwithesophagectomy．Futuretrialsshouldfocusontheidentificationof optimum regimensandselectionofpatientswhoaremostlikelytobenefitfrom specifictreatmentoptions． Esophagealcancer(Ec)jneoadjuvnattherapy；chemoradiotherapy；esophagectomy；review；randomizedcontrolledclinical trials Introduction ofrlocallyadvancedEC